ArticleAnalytical cellular pathology (Amsterdam)2026
Ophiopogonin D Alleviates Nonalcoholic Steatohepatitis via Ferroptosis Through AKT1/STAT3/HIF-1α Axis.
Article in Analytical cellular pathology (Amsterdam), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in ferroptosis and cuproptosis: implications for spinal cord injury.Molecular biology reports · 2026Review
- Ophiopogonin D Alleviates Nonalcoholic Steatohepatitis via Ferroptosis Through AKT1/STAT3/HIF-1α Axis.Analytical cellular pathology (Amsterdam) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNot enough is known about how ophiopogonin D (OP-D) works and the molecular mechanisms involved in nonalcoholic steatohepatitis (NASH). This study aimed to investigate the antifibrosis effect and underlying mechanism of OP-D in NAFLD.
methodsThe rats were fed a high-fat diet (HFD) to simulate NAFLD. After OP-D treatment or not, the rat serum lipid levels and inflammatory and ferroptosis-related factors were detected. Online databases and network pharmacology were used to collect the targets of OP-D against NASH. The effect of OP-D on AKT1, STAT3, ferroptotic markers, and fibrotic markers was determined using western blot or PCR assays.
resultsOP-D inhibited abnormal liver function, fibrotic markers (α-SMA/Col1α1), and ferroptosis-related factor (GPX4) in NASH rats. Network pharmacology proposed AKT1 and STAT3 as targets for OP-D against NASH. OP-D reduced the p-AKT and p-STAT3 in liver tissues. OP-D reduced the levels of AKT1, STAT3, and HIF-1α in model hepatic stellate cells. AKT1 and STAT3 overexpression reversed the antifibrosis and ferroptosis-induced effects of OP-D in model hepatic stellate cells.
conclusionOP-D may alleviate fibrosis in NASH by regulating ferroptosis via the AKT1/STAT3/HIF-1α axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.